化学合成。
化学合成
合成路线 1(1. 合成:34837-84-8)
产率:81%
合成条件:With hydrogenchloride In 1,4-dioxane; methanol for 18 h; Heating / reflux
实验步骤:将2-(4-氟苯基)乙酸(15.4G,0.1mol)的甲醇(600mL)溶液用氯化氢的二恶烷溶液(4N,100mL)处理,然后加热回流。 18小时 将溶液冷却并真空浓缩。 减压蒸馏残余物(55-58℃/ 0.5mmHg),得到标题化合物,为无色油状物(13.6g,81%)。#x; H NMR(300MHZ,CDCl3):δ3.66( s,2 H)3.70(s,3H)7.02(m,2H)7.24(m,2H)。
参考文献:
- [1] Patent: WO2005/19191, 2005, A2. Location in patent: Page/Page column 147 [2] Patent: US6307047, 2001, B1 [3] Patent: US5686455, 1997, A [4] Tetrahedron Letters, 2015, vol. 56, # 31, p. 4634 - 4637 [5] Angewandte Chemie - International Edition, 2018, vol. 57, # 12, p. 3233 - 3237 [6] Angew. Chem., 2018, vol. 130, # 12, p. 3287 - 3291,5 [7] Patent: US5760018, 1998, A [8] Patent: US5519048, 1996, A
合成路线 2(2. 合成:34837-84-8)
产率:98%
合成条件:for 3 - 4 h; Heating / reflux
实验步骤:例5;向含有4-氟苯基乙酸5A(5g,0.0324mol)的干燥MEOH溶液(50ML)中加入催化量的4-甲苯磺酸(0.324mmol,61mg)。将溶液回流4小时。减压浓缩所得溶液,得到淡黄色浆状物。将该物质用EtOAc(100mL)稀释,并用NAHCO 3(1M,5mL)中和。然后将有机层用H 2 O(10mL×2)洗涤,然后用盐水(10mL)洗涤,用MGSO 4干燥并过滤。浓缩滤液,得到浅黄色液体。 (5.33g,31.75毫摩尔,98%,MS M + H = 169实测值:169,1H NMR结构证实)。然后将甲酯(2.0g,11.9mmol)加入到含有NBS(2.33g,13.09mmol)的CCL4溶液(100mL)中。将反应混合物在80℃下回流3小时,得到溴化甲酯5b。将冷却的溶液通过硅胶垫过滤以除去过量的SUCININIDE,减压蒸发滤液,并将所得物质不经进一步纯化转移至下一反应。向含有胺(TBIA,2.44g(8.94mmol)/ 15mL ACN)的乙腈溶液中加入化合物5B(约2g)。在搅拌反应混合物的同时滴加三乙胺(1.70ML,12.2毫摩尔,1.5当量)。将反应混合物在环境温度下搅拌16小时。反应完成后,将反应混合物减压浓缩,并用EtOAc(25mL)稀释。将有机层用H 2 O处理,经MGSO 4干燥,并过滤。然后将滤液减压浓缩,得到化合物5c,3.29g。将异丁酰氯(0.53ML,4.99mmol,在5mL DCM中)滴加到含有化合物5C(2.0g,4.54mmol)的冷却的DCM溶液(10mL)中。在搅拌反应混合物的同时,滴加三乙胺溶液(1.27ML,2当量,在5mL DCM中)。搅拌反应混合物,同时将其温热至室温2小时。反应完成后,将反应混合物用1N HCl(20mL)处理,然后用饱和NaHCO 3水溶液处理。 NAHC03(3mL)。然后将有机层用水和盐水洗涤,经MGSO 4干燥并过滤。减压浓缩滤液,得到淡黄色浆状物。将其通过柱色谱法纯化,使用EtOAc-己烷混合物的梯度(0至25%的EtOAc)。分离的甲酯产量为2.10克,4.13毫摩尔,90.9%。将甲酯(250mg,0.50mmol)溶解在LIOH溶液(1M,THF:水(5:1)混合物)中,并剧烈搅拌3小时。通过用1N HCL溶液滴定将反应混合物中和至pH 7。然后用EtOAc(20mL)萃取所需产物。将有机层用H 2 O和盐水洗涤,经MgSO 4干燥并过滤。然后减压蒸发滤液,得到白色无定形物质5(200mg,0.40mmol,80%,MS M + H = 496,实测值:496,证实LU NMR结构)。中级1;将100g(0.64mol)4-氟苯基乙酸,0.5g(2.6mmol)对甲苯磺酸在600ml甲醇中的溶液在搅拌下回流3小时。冷却后,浓缩反应物,将残余物溶于乙酸乙酯中。有机物用饱和的NAHCO 3溶液,水和盐水洗涤。用硫酸钠干燥,过滤并浓缩,得到101.5克透明液体。 MS AP + 169.0(M + 1),AP-167.0(M-1)。
参考文献:
- [1] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 13, p. 2843 - 2866 [2] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 15, p. 4694 - 4703 [3] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 3, p. 1151 - 1156 [4] Patent: WO2005/14539, 2005, A2. Location in patent: Page/Page column 57-59; 68-69 [5] Tetrahedron, 2002, vol. 58, # 51, p. 10113 - 10126 [6] Organic letters, 2002, vol. 4, # 3, p. 371 - 373 [7] Journal of Organic Chemistry, 2009, vol. 74, # 6, p. 2598 - 2600 [8] Patent: US2013/79320, 2013, A1. Location in patent: Paragraph 0668; 0669 [9] Patent: WO2013/45451, 2013, A1. Location in patent: Page/Page column 102 [10] Journal of the American Chemical Society, 2015, vol. 137, # 32, p. 10246 - 10253 [11] Patent: US2005/107364, 2005, A1. Location in patent: Page/Page column 74 [12] Journal of Organic Chemistry, 2016, vol. 81, # 15, p. 6808 - 6815 [13] European Journal of Medicinal Chemistry, 2017, vol. 135, p. 117 - 124 [14] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 14, p. 4034 - 4049 [15] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, # 16, p. 1893 - 1895 [16] Tetrahedron, 2008, vol. 64, # 22, p. 5072 - 5078 [17] Organic Letters, 2010, vol. 12, # 17, p. 3736 - 3739 [18] Bulletin of the Korean Chemical Society, 2010, vol. 31, # 8, p. 2315 - 2321 [19] Comptes Rendus Chimie, 2011, vol. 14, # 12, p. 1071 - 1079 [20] Chemical Communications, 2012, vol. 48, # 79, p. 9936 - 9938 [21] Research on Chemical Intermediates, 2012, vol. 38, # 8, p. 1827 - 1837 [22] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 3943 - 3949 [23] Patent: WO2013/104829, 2013, A1. Location in patent: Page/Page column 23; 24 [24] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 7, p. 1677 - 1680 [25] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 3, p. 481 - 484 [26] Advanced Synthesis and Catalysis, 2015, vol. 357, # 11, p. 2479 - 2484 [27] New Journal of Chemistry, 2016, vol. 40, # 7, p. 6109 - 6119 [28] Angewandte Chemie - International Edition, 2017, vol. 56, # 14, p. 3987 - 3991 [29] Angew. Chem., 2017, vol. 129, # 14, p. 4045 - 4049,5 [30] Patent: WO2017/49069, 2017, A1. Location in patent: Paragraph 00197 [31] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 14, p. 3719 - 3735 [32] Chemical Communications, 2017, vol. 53, # 75, p. 10429 - 10432 [33] Patent: CN107286069, 2017, A. Location in patent: Paragraph 0023; 0024 [34] Journal of Chemistry, 2017, vol. 2017, [35] Organic Letters, 2018, vol. 20, # 10, p. 2997 - 3000 [36] Organic Letters, 2018, vol. 20, # 24, p. 7888 - 7892
合成路线 3(3. 合成:34837-84-8)
产率:50%
合成条件:With 3-chloro-benzenecarboperoxoic acid; copper(ll) bromide In 1,4-dioxane at 70℃; for 3 h;
实验步骤:通用方法:向m-CPBA(1.2mmol)和CuBr 2(0.1mmol)的无水1,4-二恶烷(10mL)溶液中滴加化合物1(1mmol)的溶液。 将反应混合物在指定温度下搅拌直至TLC显示起始军用化合物1的消耗。反应完成后,使反应混合物冷却至室温,并加入EtOAc(20mL)。 将所得混合物用饱和Na 2 S 2 O 3水溶液(10mL)和饱和Na 2 CO 3水溶液(10mL)洗涤。 将有机层用无水Na 2 SO 4干燥,过滤,并在减压下除去。 通过硅胶快速柱色谱法纯化残余物,得到所需产物。
参考文献:
- [1] Tetrahedron Letters, 2015, vol. 56, # 31, p. 4634 - 4637